Fennec CFO exercises 13,072 options at $5.10

FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share.

Accepted by SEC EDGAR 03/26/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.

Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.

Insider Trade Summary

13,072 shares exercised/converted

Exercise 2 txns

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Stock Options	13,072	$5.10	$67K
Exercise	Common shares	13,072	$5.10	$67K

Holdings After Transaction: Stock Options — 801,045 contracts (Direct); Common shares — 256,656 shares (Direct)

Holdings Before and After: Stock Options, 814,117 to 801,045 contracts (Direct); Common shares, 243,584 to 256,656 shares (Direct)

Footnotes (1)

1. F1. Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fennec Pharmaceuticals (FENC) disclose in this Form 4 for its CFO?

Fennec Pharmaceuticals reported that its CFO, Robert Andrade, exercised stock options to acquire 13,072 common shares at $5.10 per share. The transaction is an option exercise, not an open-market trade, and increases his directly held common share position.

Did the Fennec (FENC) CFO buy or sell shares on the open market in this filing?

No, the CFO did not buy or sell shares on the open market. He exercised stock options, converting 13,072 derivative securities into 13,072 common shares at a fixed exercise price of $5.10 per share, a standard compensation-related event.

How many Fennec Pharmaceuticals (FENC) shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Robert Andrade directly holds 256,656 common shares of Fennec Pharmaceuticals. This post-transaction balance reflects the addition of 13,072 shares obtained through the exercise of stock options at $5.10 per share.

What is the strike price and structure of the Fennec (FENC) CFO’s exercised options?

The CFO exercised options with a strike price of $5.10 per share, converting them into common shares. According to the footnote, these options carried a $5.10 exercise price and an original expiration date of June 27, 2027, before being exercised.

Is the Fennec Pharmaceuticals (FENC) CFO’s Form 4 transaction a routine compensation event?

Yes, the transaction appears as a routine compensation-related option exercise. The Form 4 shows an option exercise (code M) where 13,072 derivative options were converted into 13,072 common shares at $5.10, without any reported concurrent sale of those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	03/26/2026		M		13,072	A	$5.1	256,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	$5.1	03/26/2026		M			13,072	06/27/2017	06/27/2027	Options	13,072	$5.1	801,045	D

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with strike price of $5.10 and an expiration date of June 27, 2027.

	/s/ Robert Andrade	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)